Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems.

[1]  F. Nosten,et al.  Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.

[2]  P. Newton,et al.  A Major Genome Region Underlying Artemisinin Resistance in Malaria , 2012, Science.

[3]  Robert W. Snow,et al.  Mobile Phone Text Messaging: Tool for Malaria Control in Africa , 2012, PLoS medicine.

[4]  Nicholas J White,et al.  Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator , 2011, Malaria Journal.

[5]  Robert W Snow,et al.  The effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial , 2011, The Lancet.

[6]  M. Laufer,et al.  Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data , 2011, Malaria Journal.

[7]  C. Roper,et al.  The Transit Phase of Migration: Circulation of Malaria and Its Multidrug-Resistant Forms in Africa , 2011, PLoS medicine.

[8]  L. Decosterd,et al.  Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure. , 2010, The Journal of infectious diseases.

[9]  O. Stine,et al.  Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. , 2010, The Journal of infectious diseases.

[10]  C. Roper,et al.  Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. , 2010, Trends in parasitology.

[11]  H. Mshinda,et al.  Drug coverage in treatment of malaria and the consequences for resistance evolution - evidence from the use of sulphadoxine/pyrimethamine , 2010, Malaria Journal.

[12]  Lorenz von Seidlein,et al.  Artemisinin resistance: current status and scenarios for containment , 2010, Nature Reviews Microbiology.

[13]  S. Groseclose,et al.  Implementing integrated disease surveillance and response: Four African countries' experience, 1998–2005 , 2010, Global public health.

[14]  Andrew J Tatem,et al.  International population movements and regional Plasmodium falciparum malaria elimination strategies , 2010, Proceedings of the National Academy of Sciences.

[15]  F. Nosten,et al.  Exploring the Contribution of Candidate Genes to Artemisinin Resistance in Plasmodium falciparum , 2010, Antimicrobial Agents and Chemotherapy.

[16]  R. Price,et al.  In vivo parasitological measures of artemisinin susceptibility. , 2010, The Journal of infectious diseases.

[17]  Margaret Chan,et al.  Meeting the Demand for Results and Accountability: A Call for Action on Health Data from Eight Global Health Agencies , 2010, PLoS medicine.

[18]  R. Bate,et al.  Drug procurement, the Global Fund and misguided competition policies , 2009, Malaria Journal.

[19]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[20]  B. Sharp,et al.  Multiple Origins and Regional Dispersal of Resistant dhps in African Plasmodium falciparum Malaria , 2009, PLoS medicine.

[21]  R. Snow,et al.  Malaria case-management under artemether-lumefantrine treatment policy in Uganda , 2008, Malaria Journal.

[22]  Umberto D'Alessandro,et al.  The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance , 2008, Malaria Journal.

[23]  S. Briolant,et al.  Antimalarial drug use in general populations of tropical Africa , 2008, Malaria Journal.

[24]  R. Snow,et al.  From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia , 2008, Malaria Journal.

[25]  U. d’Alessandro,et al.  Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: a review of epidemiologic field evidence. , 2007, The American journal of tropical medicine and hygiene.

[26]  R. Snow,et al.  The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya , 2007, Malaria Journal.

[27]  J. Cox,et al.  Detecting Epidemic Malaria, Uganda , 2007, Emerging infectious diseases.

[28]  P. Ringwald,et al.  Efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia , 2006, Tropical medicine & international health : TM & IH.

[29]  E. Ahmed,et al.  From chloroquine to artemisinin-based combination therapy: the Sudanese experience , 2006, Malaria Journal.

[30]  P. Newton,et al.  Manslaughter by Fake Artesunate in Asia—Will Africa Be Next? , 2006, PLoS medicine.

[31]  S. Abdulla,et al.  The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania , 2006, Tropical medicine & international health : TM & IH.

[32]  Andrew P. Morse,et al.  Malaria early warnings based on seasonal climate forecasts from multi-model ensembles , 2006, Nature.

[33]  M. Peiris,et al.  International Health Regulations (2005) , 2005, The Lancet.

[34]  R. Snow,et al.  Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study , 2005, BMJ : British Medical Journal.

[35]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[36]  S. Mharakurwa.  Plasmodium falciparum transmission rate and selection for drug resistance: a vexed association or a key to successful control? , 2004, International journal for parasitology.

[37]  M. Mayxay,et al.  Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross‐sectional survey on the prevalence of fake antimalarials , 2004, Tropical medicine & international health : TM & IH.

[38]  Joel Schwartz,et al.  Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia II. Weather-based prediction systems perform comparably to early detection systems in identifying times for interventions , 2004, Malaria Journal.

[39]  D. Durrheim,et al.  The process of changing national malaria treatment policy: lessons from country-level studies. , 2004, Health policy and planning.

[40]  B. Sharp,et al.  Intercontinental Spread of Pyrimethamine-Resistant Malaria , 2004, Science.

[41]  Ian M Hastings,et al.  Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. , 2004, The American journal of tropical medicine and hygiene.

[42]  R. Snow,et al.  WHO, the Global Fund, and medical malpractice in malaria treatment , 2004, The Lancet.

[43]  U. d’Alessandro,et al.  History, Dynamics, and Public Health Importance of Malaria Parasite Resistance , 2004, Clinical Microbiology Reviews.

[44]  L. Corey,et al.  The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy , 2003, Tropical medicine & international health : TM & IH.

[45]  J. Kublin,et al.  Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. , 2003, The Journal of infectious diseases.

[46]  E. van Marck,et al.  Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[47]  N. White,et al.  The de novo selection of drug–resistant malaria parasites , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[48]  John C. Wootton,et al.  Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum , 2002, Nature.

[49]  N. White,et al.  The evolution of drug-resistant malaria: the role of drug elimination half-life. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[50]  J. Kublin,et al.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. , 2002, The Journal of infectious diseases.

[51]  B. Karoumi,et al.  Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience , 2001, Tropical medicine & international health : TM & IH.

[52]  O. Doumbo,et al.  Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria , 2001, The Lancet.

[53]  Ashutosh Kumar Singh,et al.  Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. , 2001, The Journal of infectious diseases.

[54]  B. Karoumi,et al.  Vitamin therapy and prevention of neural tube defects , 2001 .

[55]  U. d’Alessandro,et al.  Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.

[56]  E. Nduati,et al.  Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. , 2000, The Journal of infectious diseases.

[57]  A. Nzila,et al.  Towards an Understanding of the Mechanism of Pyrimethamine-Sulfadoxine Resistance in Plasmodium falciparum: Genotyping of Dihydrofolate Reductase and Dihydropteroate Synthase of Kenyan Parasites , 2000, Antimicrobial Agents and Chemotherapy.

[58]  P. Olliaro,et al.  Averting a malaria disaster , 1999, The Lancet.

[59]  Nájera-Morrondo Ja.  Prevention and control of malaria epidemics. , 1999 .

[60]  C. Plowe,et al.  The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. , 1997, Parasitology today.

[61]  O. Doumbo,et al.  Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. , 1996, The American journal of tropical medicine and hygiene.

[62]  W. Wernsdorfer.  Epidemiology of drug resistance in malaria. , 1994, Acta tropica.

[63]  R. Steketee,et al.  Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. , 1993, The Journal of infectious diseases.

[64]  Thomas E. Wellems,et al.  Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross , 1990, Nature.

[65]  D. Payne.  Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? , 1988, Parasitology today.

[66]  S. Teutsch,et al.  CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM EAST AFRICA: Cultivation and Drug Sensitivity of the Tanzanian I/CDC Strain from an American Tourist , 1979, The Lancet.

[67]  Andrew Weber,et al.  International Health Regulations , 1971 .

[68]  Clyde Df.  Drug resistance of malaria parasites in Tanzania. , 1966 .

[69]  T. Harinasuta,et al.  Chloroquine-resistant falciparum malaria in Thailand. , 1965, Lancet.

[70]  R. Snow,et al.  The eff ect of mobile phone text-message reminders on Kenyan health workers ’ adherence to malaria treatment guidelines : a cluster randomised trial , 2011 .

[71]  Organização Mundial de Saúde,et al.  World malaria report 2011 , 2011 .

[72]  J. Nájera.  Prevention and control of malaria epidemics. , 1999, Parassitologia.

[73]  S Lemeshow,et al.  Lot quality assurance sampling: single- and double-sampling plans. , 1991, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[74]  D. Clyde.  Drug resistance of malaria parasites in Tanzania. , 1966, East African medical journal.